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SYNOPSIS
Simvastatin acid (SVA) has been reported to stimulate bone formation by increasing expression of BMP-2 in osteoblasts. Because of the ir multi-functional characteristics and bioadaptability, cyclodextrins (CDs) are capable of forming inclusion complexes with many drugs by including a whole drug molecule inside their cavity. In the present study, we prepared SVA/CD inclusion complex solutions with different pHs. These were then used to determine the ir SVA release properties after coating on titanium substrates and clarify the characteristics of the SVA/CD complexes themselves. The results showed that the lower the pH value of the solution, the lower the release kinetics of the SVA, and that the amount of crystalline complexes in the coatings increased with decrease in pH. These results suggest that the release rate of SVA depends on the pH of the solution and the concomitant crystallinity of the coatings.
INTRODUCTION
Simvastatin (SV), a liposoluble statin [inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase], is widely used for lowering cholesterol levels. Recently, it has been reported to stimulate bone formation, both in vitro and in vivo, in animal osteoporosis models 1 , 2 ) . This phenomenon was associated with increased expression of the bone morphogenetic protein-2 (BMP-2) gene in osteoblasts. This suggests that controlled release of simvastatin by means of its topical application around dental and maxillofacial implants would promote osteogenesis in surrounding bone tissue 3) , and would offer potential in bone regeneration at bone-deficient areas. Furthermore, one distinct advantage of simvastatin for local stimulation of bone formation would be its low manufacturing cost compared to that of direct administration of recombinant proteins such as BMPs. There would also be a reduced possibility of eliciting antibody responses.
In general, SV is administered by gavage, and requires hepatic conversion to metabolically active ß-hydroxy acid (SVA) to become medicinally active 4, 5) . Therefore, for local administration, SV would have to be hydrolyzed to SVA first. We have reported an immobilization method for SVA around implants in order to promote osteogenesis 6) . However, a drug delivery system (DDS), in which a carrier was used to deliver SVA to bone-deficient areas, would offer a more powerful strategy for improving bone quality. This would necessitate achieving slow SVA release during the bone formation process after wound healing. Therefore, an effective carrier would be required to express the pharmacological effects of SVA.
Cyclodextrins (CDs), which are recognized as an important group of pharmaceutical excipients, are one such candidate 7) . They are cyclic oligosaccharides consisting of (a-1, water-soluble, but the hydrophobic cavity provides a microenvironment for appropriately sized nonpolar molecules. They are capable of forming inclusion complexes with many drugs by including a whole drug molecule inside their cavity. In an aqueous solution, the complexes are readily dissociated, and free drug molecules are in relatively rapid dynamic equilibrium with drug molecules bound within the CD cavity 8, 9, 10, 11) . These noncovalent complexes show new physicochemical characteristics, when compared with the guest molecules, which include better stability, higher aqueous solubility, increased bioavailability, and fewer undesirable side effects. Therefore, if it were possible to form SVA/CD inclusion complexes and control the ir solubility, it would be possible to control the release properties of SVA.
Since hydrophobic interaction between SVA and CD would be the main mechanism for forming SVA/CD inclusion complexes, it is important to control the hydrophobicity of the guest molecule SVA. SVA hydrophobicity is influenced by pH value, as the characteristic dissociation of carboxyl groups in SVA molecules depends on pH 8, 12, 13) . The crystallinity of the inclusion complexes would also influence the release character of the SVA, which would be concomitant to the solubility of SVA/CD complexes.
Consequently, the purpose of the present study was to investigate the possibility of controlling the release rate of SVA. To meet this demand, we prepared SVA/CD solutions with different pH values, and evaluated the ir SVA release properties from SVA/CD complex coatings on titanium substrates, and clarified the characteristics of the SVA/CD complexes themselves.
MATERIALS AND METHODS

Preparation of SVA
Commercially available simvastatin {(+)-(1 S, 3 R, 7 S, 8 S, 8a R)-1, 2, 3, 7, 8, 8a-hexahydro-3, 
Preparation of SVA/CD solution
ß-cyclodextrin (CD, Wako Pure Chemical Industries, Osaka, Japan) was used to prepare the inclusion complexes (Fig. 2) . 25 mg CD was added to 5mL SVA solution (1000ppm 6) ) at 65ºC and stirred; then, the following three solutions, each with a different pH, were prepared by addition of the 0.1N HCl solution. SVA solution (1000 ppm) was also used as a control. 
SVA release assay from coatings
Surfaces of cp-titanium (Ti) plates (diameter: 30 mm, thickness: 2 mm) were blasted with 50 µm-alumina, and ultrasonically cleaned with acetone and distilled water for 20 min. Surfaces were subjected to ultra-vio let radiation before coating to improve wettability. Subsequently, 50 6 µL each of SVA/CD solution and SVA solution were heated to 65ºC and coated onto the titanium surfaces under air-drying at 25ºC
These coated specimens were immersed in distilled water and stored for 0.5, 1, 3, 7 and 21 days at 37ºC. At each time interval, absorbance of released SVA in the solution was measured using the UV-Visible spectrophotometer (V-660, JASCO Corporation, Tokyo, Japan) at a wavelength of 239.1 nm 14, 15) . The cumulated concentration of the SVA was calculated using a previously determined working curve.
Estimation of degree of substitution
Degree of substitution 16) , that is, the ability to form inclusion complexes, was estimated to 
Characterization of coatings
The crystallinity of films coated onto the mirror-polished titanium was determined by X-ray diffraction using a thin film attachment (XRD, RINT-2500, Rigaku, Tokyo, Japan), with an X-ray source of Cu-ka1, and at a power of 50 kV/300 mA. These films were coated with the SVA/CD solution, as described in SVA release assay.
The surface morphology of the coatings on the blasted titanium surfaces was observed under a scanning electron microscope (SEM, JSM-6340F, JEOL, Japan). The specimens were coated with Au-Pd alloy. Accelerating voltage was set at 15.0 kV.
Statistical analysis
The data (n=5) were analyzed for statistical significance using an analysis of variance (ANOVA) followed by Scheffe's test for multiple comparisons. 
RESULTS
Release behavior of SVA from coatings on titanium substrates
Characterization of coatings
X-ray diffraction profiles are shown in Fig.6 . The diffraction peaks between 35 and 45 degrees in all specimens were attributed to the titanium substrate. The SVA coatings were almost completely amorphous, whereas the CD coatings showed crystalline patterns at between 3 and 15 degrees with raw ß-CD. A clear new crystalline peak, which was not identified by JPCDS cards, was observed at around 28.3 degrees on the SVA/CD coatings. This peak increased with decrease in pH value, whereas the peaks attributed to ß-CD decreased with decrease in pH value.
This behavior may be explained by the formation of inclusion complexes. 
DISCUSSION
The objective of the present study was to clarify the release character of SVA from SVA/CD coatings with different pHs. The results showed that the lower the pH values of the solution, the lower the release kinetics of the SVA, indicating that the release character of SVA can be controlled by adjusting the pH value. Release character is influenced by the degree of substitution and the crystallinity of the coatings.
Degree of substitution plays an important role in balancing CD water solubility and its ability to form complexes. Raising degree of substitution induces binding of guests to CDs by increasing the surface area available for binding. In this study, the results showed that the lower the pH value of the SVA/CD solution, the higher the degree of substitution. This is a consequence of the different hydrophobic character of the guest molecule, SVA . SVA has a carboxylic acid (pKa = 4.18) which is almost completely dissociated at pH 6.8, with the carboxylic group being gradually deionized with decrease in pH 8, 16) . Therefore, at a low pH value, SVA becomes stable and hydrophobic, resulting in hydrophobic interaction between SVA and CD being enhanced.
Temperature changes can also affect drug/CD complexes, in terms of degree of substitution. In most cases, increasing the temperature decreases the magnitude of the apparent stability constant of the drug/CD complex, possibly due to subsequent reduction in drug/CD interaction forces such as van der Waals and hydrophobic forces 17, 18) . In this study,
we believe that few SVA/CD complexes occurred at 65ºC. However, the number of complexes increased with decrease in temperature during the drying process.
The crystallinity of the SVA/CD complexes influenced the solubility of the coatings 8) . A clear crystalline peak was observed by XRD analysis, showing an increase with decrease in pH value. This peak appeared to originate in the inclusion complexes of SVA/CD formed in the coatings. These crystalline structures may have retarded the dissolution rate of the coatings, resulting in delayed release of SVA.
In this study, ß-CD was selected as first choice to form inclusion complexes as it has the least solubility in water among the most abundant natural CDs. Further study is necessary to evaluate other CDs that promote slow release of SVA. Hydrophobic CDs, such as alkylated and acylated derivatives, are useful as slow-release carriers in prolonged release formulations of water-soluble drugs 19, 20, 21) .
In conclusion, the results of the present study indicate that the number of SVA/CD complexes formed depended on the pH of the solution, and that subsequent release of SVA 
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